870194-52-8

Upstream product

• 496856-45-2 (3-chloro-4-cyanophenyl)acetic acid methyl ester 
• 64-18-6 formic acid 
• 34841-49-1 3-chloro-4-formylbenzeneacetic acid 
• 57017-95-5 methyl 3-chloro-4-hydroxyphenylacetate 
• 33697-81-3 (3-chloro-4-hydroxy-phenyl)-acetic acid 
• 496856-44-1 methyl 2-(3-chloro-4-(triuoromethylsulfonyloxy)phenyl)acetate 

Downstream Products

• 927180-01-6 2-chloro-4-(methoxycarbonylmethyl)benzoic acid 
• 870520-87-9 (3-chloro-4-hydroxymethyl-phenyl)-acetic acid methyl ester 
• 870195-37-2 5-(2-chloro-4-methoxycarbonylmethyl-phenyl)-3-phenyl-isoxazole-4-carboxylic acid 
• 870195-38-3 C₁₉H₁₃Cl₂NO₄ 
• 919287-41-5 (3-chloro-4-{5-[4-(2,4-dichloro-phenoxy)-butyryl]-4-phenyl-isoxazol-3-yl}-phenyl)-acetic acid methyl ester 
• 919284-97-2 (3-chloro-4-{4-[2-(2,4-dichloro-phenoxy)-ethyl-carbamoyl]-5-phenyl-isoxazol-3-yl}-phenyl)-acetic acid methyl ester 
• 870194-57-3 (3-chloro-4-{5-methyl-4-[2-(2-nitro-4-trifluoromethyl-phenoxy)-ethoxymethyl]-isoxazol-3-yl}-phenyl)-acetic acid methyl ester 
• 1047643-60-6 (3-chloro-4-{4-[2-(2,4-dichloro-phenoxy)-ethoxymethyl]-5-phenyl-isoxazol-3-yl}-phenyl)-acetic acid methyl ester 
• 919283-66-2 (4-{4-[2-(2,4-bis-trifluoromethyl-phenoxy)-ethylcarbamoyl]-5-methyl-isoxazol-3-yl}-3-chloro-phenyl)-acetic acid methyl ester 
• 919283-27-5 (3-chloro-4-{5-methyl-4-[2-(2-nitro-4-trifluoromethyl-phenoxy)-ethylcarbamoyl]-isoxazol-3-yl}-phenyl)-acetic acid methyl ester 
• 870194-70-0 (3-chloro-4-{4-[2-(2,4-dichloro-phenoxy)-ethylcarbamoyl]-5-phenyl-isoxazol-3-yl}-phenyl)-acetic acid 
• 870194-95-9 (3-chloro-4-{4-[2-(2,4-dichloro-phenoxy)-ethylcarbamoyl]-5-phenyl-isoxazol-3-yl}-phenyl)-acetic acid methyl ester 

Relevant academic research and scientific papers

3,4,5-Trisubstituted isoxazoles as novel PPARδ agonists: Part 1

We report the identification of a novel series of trisubstituted isoxazoles as PPAR activators from a high-throughput screen. A series of structural optimizations led to improved efficacy and excellent functional receptor selectivity for PPARδ. The isoxazoles represent a series of agonists which display a scaffold that lies outside the typical PPAR agonist motif.

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR .

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.